JPS63250319A - Pharmaceutical preparation suitable in oral cavity - Google Patents
Pharmaceutical preparation suitable in oral cavityInfo
- Publication number
- JPS63250319A JPS63250319A JP8303687A JP8303687A JPS63250319A JP S63250319 A JPS63250319 A JP S63250319A JP 8303687 A JP8303687 A JP 8303687A JP 8303687 A JP8303687 A JP 8303687A JP S63250319 A JPS63250319 A JP S63250319A
- Authority
- JP
- Japan
- Prior art keywords
- oral cavity
- preparation
- mucosa
- nifedipine
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000214 mouth Anatomy 0.000 title abstract description 15
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229960001597 nifedipine Drugs 0.000 claims abstract description 20
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000004373 Pullulan Substances 0.000 claims abstract description 12
- 229920001218 Pullulan Polymers 0.000 claims abstract description 12
- 235000019423 pullulan Nutrition 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004877 mucosa Anatomy 0.000 abstract 4
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 208000024335 physical disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 description 10
- 210000002200 mouth mucosa Anatomy 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
■）産業上の利用分野
本発明はプルランと薬物成分、殊にニフェジピンを必須
成分とする口腔粘膜あるいは歯肉に適用する簡便な口腔
内投与製剤及び製法に関する。DETAILED DESCRIPTION OF THE INVENTION (1) Field of Industrial Application The present invention relates to a simple intraorally administered formulation and manufacturing method that is applied to the oral mucosa or gingiva and contains pullulan and drug components, particularly nifedipine, as essential components.
２）従来技術との関係
近年、薬物を標的部位に望ましい１ｒ：１度で送り込む
と同時に他の部位への移行を極力抑えて、薬物の本来持
つ汀効性を上手に引き出し、既存の適用方法での弊害あ
るいは限界を、投与形態を工夫することで乗り越えよう
とするドラッグデリバリ−システムの開発が盛んに試み
られている。その一つ適用方法として口腔内への薬物投
与が検討されている。2) Relationship with conventional technology In recent years, existing application methods have been developed to deliver drugs to the target site at the desired rate of 1r:1, while at the same time suppressing migration to other sites as much as possible to bring out the drug's inherent therapeutic effect. Many attempts have been made to develop drug delivery systems that overcome the disadvantages or limitations of drug delivery systems by devising dosage forms. Intraoral drug administration is being considered as one application method.
一方、ニフェジピンはカルシウム拮抗剤で、狭心症や高
血圧の治療薬として汎用されている有用な薬物である。On the other hand, nifedipine is a calcium channel blocker and is a useful drug commonly used as a treatment for angina pectoris and hypertension.
このニフェジピンは口腔粘膜より速やかに吸収されるの
で、狭心症のように緊急性を必要とする場合にはニフェ
ソビン軟カプセルを噛み砕いて使用する方法が用いられ
ている。この場合、ニフェジピン血清濃度は速やかに上
昇するが、半減期１時間程度で、比較的早い速度で減少
するので効力が持続しないという欠点を有している。Since nifedipine is rapidly absorbed through the oral mucosa, in urgent cases such as angina pectoris, nifesobin soft capsules are crushed and used. In this case, the serum concentration of nifedipine increases rapidly, but has a half-life of about 1 hour and decreases at a relatively rapid rate, so it has the disadvantage that its efficacy does not last.
本発明者らは、口腔粘膜より速やかに吸収するニフェジ
ピンを口腔内に長時間滞留させるとともに、定量的に放
出させることにより、速効性と持効性を有する製剤を開
発できると考えた。The present inventors thought that by allowing nifedipine, which is rapidly absorbed through the oral mucosa, to remain in the oral cavity for a long time and releasing it quantitatively, it would be possible to develop a formulation that has both immediate and sustained effects.
従来は、このような目的の為に、製剤を口腔に付着させ
て固定し、そこから徐々に有効成分を放出させる方法が
用いられている。付着機能と薬物放出調節機能を兼ね備
えた基剤としては、ヒドロキシプロピルセルロース、カ
ルボキシメチルセルロースナトリウム、メチルセルロー
ス、ヒドロキシプロピルメチルセルロースなどの結合剤
が検討されてきた。Conventionally, for this purpose, a method has been used in which a preparation is adhered and fixed to the oral cavity, and the active ingredient is gradually released from there. Binders such as hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, and hydroxypropyl methyl cellulose have been investigated as bases that have both adhesion and drug release control functions.
しかし、これらの結合剤は打錠し難＜、また、生体への
接着力が弱（、更に水と接触してゲル化し、薬物の放出
後も長時間口腔粘膜に残って口腔内で違和感を生じさせ
るという欠点を仔している。However, these binders are difficult to tablet and have weak adhesion to living organisms (furthermore, they gel on contact with water and remain in the oral mucosa for a long time even after the drug has been released, causing discomfort in the oral cavity. It has the disadvantage of causing problems.
３）発明の目的
本発明者らは、それらの欠点を解消すべく鋭意研究した
結果、プルランを基剤として用いることによリ、その目
的が達成されることを見いだし本発明を完成した。3) Purpose of the Invention As a result of intensive research aimed at solving these drawbacks, the present inventors have found that the purpose can be achieved by using pullulan as a base material, and have completed the present invention.
プルランは糖の一種で可食性であるが、その性質は従来
、十分には解明されていなかった。Pullulan is a type of sugar that is edible, but its properties have not been fully elucidated.
本発明者らは、プルランの性質につき、種々検討した結
果、プルランには欠配の有利な性質があること、また、
池の賦形剤、結合剤と均一に混合してもその性質がなく
ならないことも明らかにすることが出来た。As a result of various studies on the properties of pullulan, the present inventors found that pullulan has an advantageous property of lacking
We were also able to demonstrate that even when mixed uniformly with Ike's excipients and binders, its properties do not disappear.
その性質とは、生体膜によく付着し、水にはゲル化する
ことな（よく溶けるが、その溶解速度は遅く、また、分
子量によってその溶解速度が異なることである。その上
、その溶液は粘度が低く、口腔内での違和感を生じるこ
とがない。Its properties are that it adheres well to biological membranes and does not gel in water (it dissolves well, but its dissolution rate is slow, and its dissolution rate varies depending on its molecular weight. It has a low viscosity and does not cause discomfort in the oral cavity.
このようにして、プルランは口腔内投与製剤の基剤とし
て最適であることがわかった。In this way, pullulan was found to be optimal as a base for oral preparations.
４）発明の詳細な説明
口腔内付着基剤としてプルラン、有効成分としてニフェ
ジピンを用いる口腔内投与型の錠剤殊に易溶層と持続層
とよりなる錠剤並びにその製造方法である。4) Detailed Description of the Invention The present invention is an orally administered tablet using pullulan as an intraoral adhesion base and nifedipine as an active ingredient, particularly a tablet comprising an easily soluble layer and a persistent layer, and a method for producing the same.
本発明の製剤には、公知の賦形剤、安定化剤、滑沢剤、
色素などを添加することができる。The formulation of the present invention includes known excipients, stabilizers, lubricants,
Colorants and the like can be added.
５）発明の効果
プルランを口腔内投与製剤の基剤として使用して製造し
た錠剤は欠配効果を汀する。5) Effects of the invention Tablets manufactured using pullulan as a base for oral preparations suppress the dispensing effect.
（１）製剤方法が節用である。(1) The formulation method is conservative.
（２）錠剤を口腔に投与したとき、口腔粘膜あるいは歯
肉によく付若し、口腔での違和感がなく、使用し易い。(2) When the tablet is administered into the oral cavity, it sticks well to the oral mucosa or gums, does not cause discomfort in the oral cavity, and is easy to use.
（３） ｆ！Ａ剤を口腔内の歯肉に投与すると、口腔粘
膜からニフェジピンが速やかに吸収され、長時間安定し
たニフェジピンの血中濃度を維持する。(3) f! When Agent A is administered to the gingiva in the oral cavity, nifedipine is rapidly absorbed from the oral mucosa and maintains a stable blood concentration of nifedipine for a long period of time.
（４）過投与の場合、容易に直ちに製剤を除去すること
ができる。(4) In case of overdosing, the preparation can be easily and immediately removed.
６）実施例
以下、本発明の実施例を示し、更に具体的に説明するが
、これらは決して、本発明の範囲を限定するものでない
。6) Examples Hereinafter, examples of the present invention will be shown and explained in more detail, but these are not intended to limit the scope of the present invention.
実施例 に
フェジピ７１０ｇ及びポリビニルピロリドンに−３０（
以下ＰＶＰ Ｋ−３０と呼ぶ）４０ｇをとり、遮光し
たフラスコに入れ、エタノール５００■１に溶かした後
、エバポレーターを用いて溶媒を除去し、ニフェジピン
・ＰｖＰ Ｋ−３０（１：４）を得た。このニフェジピ
ン・ＰＶＰ Ｋ−３０（１：４）９．５ｇにタルク０
．５ｇを加えて乳鉢中でよく混合した（以下、易７１１
ｙ層と呼ぶ）。Example: 710 g of fezipi and -30 g of polyvinylpyrrolidone (
Take 40 g of PVP K-30 (hereinafter referred to as PVP K-30), put it in a light-shielded flask, dissolve it in 500 μl of ethanol, and remove the solvent using an evaporator to obtain nifedipine/PvP K-30 (1:4). . This nifedipine/PVP K-30 (1:4) 9.5g and talc 0
．． 5g was added and mixed well in a mortar (hereinafter referred to as Yi 711).
(referred to as the y layer).
別に、ニフェジピン５ｐｖｐ Ｋ−３０（１：４）Ｌ
ｏｇをとり、プルラン（平均分子ＩＩ ２００．００
０ ”）４０ｇを加えて乳鉢中でよく混合した（以下、
持続層と呼ぶ）。Separately, nifedipine 5pvp K-30 (1:4)L
og, pullulan (average molecule II 200.00
0'') was added and mixed well in a mortar (hereinafter referred to as
(called the persistence layer).
上記易溶層２６■ｇを直径１０關の臼に入れて軽く圧縮
し、その上に持続！！１２５＋ｓｇを入れて６００ｋｇ
ＩＣ＋／で打錠して、三層錠にフェリピン１０腸ｇを含
有する）を得た。Put 26g of the above easily soluble layer into a mortar with a diameter of 10 mm, compress it lightly, and keep it on top! ! 600kg including 125+sg
The tablet was compressed using IC+/ to obtain a three-layer tablet containing 10 g of felipin.
こうして製造した三層錠は易溶層（２［ｆｍｇ／錠）に
ニフェジピン６■ｇを含「シ、持続層（１２８ｍｇ／錠
）にニフェジピンＳ腸ｇを含有している（第１図参照）
。The three-layer tablet thus produced contains 6 g of nifedipine in the easily soluble layer (2 fmg/tablet) and 6 g of nifedipine in the persistent layer (128 mg/tablet) (see Figure 1).
.
この三層錠について、日本薬局方−一般試験法・溶出試
験法の第２法（パドル法）を準用して、溶出液に水を用
いて溶出試験を実施した。その際、三層錠は３ｃ膳ｘ３
ｃｍのガラス板に持続層側を付着させて容器内に沈めた
。その結果は第１表及び添付第２図に示されている。For this three-layer tablet, a dissolution test was carried out using water as the dissolution solution, applying method 2 (paddle method) of the Japanese Pharmacopoeia - General Test Methods/Dissolution Test Method. At that time, three-layer tablets are 3 c meals x 3
The sustaining layer side was attached to a cm glass plate and submerged in a container. The results are shown in Table 1 and attached Figure 2.
第１表 三層錠の溶出試験結果
次に、この三層錠を無麻酔のピーグル犬（３頭）の口腔
内の歯肉に持続層側を付着させて投与し、血清中のニフ
ェジピン濃度を測定した。Table 1 Dissolution test results for three-layer tablets Next, the three-layer tablets were administered with the continuous layer side attached to the gingiva in the oral cavity of unanesthetized pegle dogs (3 dogs), and the nifedipine concentration in the serum was measured. did.
その結果は欠配第２表及び添付第３図に示されている。The results are shown in Table 2 and attached Figure 3.
第２表 二層錠投与後のピーグル犬の 血清中ニフェジピン濃度Table 2: Pegle dogs after administration of double-layer tablets Serum nifedipine concentration
添付■ｌないし３図はいづれも本発明の説明図である。
代理人 弁理士（Ｅ３３３４）砂川 五部図面の浄吉（
内容に変更なし）
［ニフェジピン ５ｍｇ含有コ
第１図 二層錠
時間（分）
第２図 二層錠の溶出試験結果
第３図 二層錠投与後のピーグル犬のニフェジピン血清
中１度手続補正書（方式）と
１、事件の表示
昭和６２年特許願第０８３０３６号
２、発明の名称
口腔内に適用する製剤
３、補正をする者
事件との関係：特許出願人
居所 大阪府松原市西大塚１−３−４０名称 藤本製薬
株式会社
代表者 藤本 部分
４、代理人
住所 東京都渋谷区神宮前２−２−３９−４１７昭和６
２年６月３日（同年：６月３０日）６、補正の対象
適正な図面Attached Figures 1 to 3 are all explanatory diagrams of the present invention. Agent: Patent attorney (E3334) Sunagawa, Jokichi of the five-part drawing (
No change in content) [Nifedipine containing 5 mg Figure 1 Double-layer tablet time (minutes) Figure 2 Dissolution test results of the double-layer tablet Figure 3 Amendment form for nifedipine serum 1st degree procedure in pegle dogs after administration of the double-layer tablet (Method) and 1. Indication of the case Patent Application No. 083036 of 1983 2. Name of the invention Preparation for oral application 3. Person making the amendment Relationship to the case: Patent applicant residence 1- Nishi-Otsuka, Matsubara City, Osaka Prefecture 3-40 Name Fujimoto Pharmaceutical Co., Ltd. Representative Fujimoto Part 4, Agent Address 2-2-39-417 Jingumae, Shibuya-ku, Tokyo Showa 6
June 3, 2016 (June 30, 2016) 6. Appropriate drawings to be amended.
Claims (3)
与製剤(1) Orally administered preparation containing pullulan and drug components as essential ingredients
範囲１の口腔内投与製剤(2) Oral administration formulation according to claim 1, which uses nifedipine as a drug component
範囲１の口腔内投与製剤の製造法(3) A method for producing an oral preparation according to claim 1, which uses nifedipine as a drug component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8303687A JPS63250319A (en) | 1987-04-06 | 1987-04-06 | Pharmaceutical preparation suitable in oral cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8303687A JPS63250319A (en) | 1987-04-06 | 1987-04-06 | Pharmaceutical preparation suitable in oral cavity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63250319A true JPS63250319A (en) | 1988-10-18 |
Family
ID=13790990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8303687A Pending JPS63250319A (en) | 1987-04-06 | 1987-04-06 | Pharmaceutical preparation suitable in oral cavity |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63250319A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| WO2017186399A1 (en) * | 2016-04-29 | 2017-11-02 | Henkel Ag & Co. Kgaa | Toothpaste for improving gum adhesion |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61267511A (en) * | 1985-05-20 | 1986-11-27 | Nitto Electric Ind Co Ltd | Disease-curing material |
| JPS62135417A (en) * | 1985-12-09 | 1987-06-18 | Sato Seiyaku Kk | Filmy pharmaceutical |
| JPS63152311A (en) * | 1986-08-08 | 1988-06-24 | Nippon Sukuibu Kk | Sustained release preparation for oral cavity |
-
1987
- 1987-04-06 JP JP8303687A patent/JPS63250319A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61267511A (en) * | 1985-05-20 | 1986-11-27 | Nitto Electric Ind Co Ltd | Disease-curing material |
| JPS62135417A (en) * | 1985-12-09 | 1987-06-18 | Sato Seiyaku Kk | Filmy pharmaceutical |
| JPS63152311A (en) * | 1986-08-08 | 1988-06-24 | Nippon Sukuibu Kk | Sustained release preparation for oral cavity |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| US6923981B2 (en) | 1998-09-25 | 2005-08-02 | Warner-Lambert Company | Fast dissolving orally consumable films |
| US7025983B2 (en) | 1998-09-25 | 2006-04-11 | Warner-Lambert Company Llc | Fast dissolving orally consumable films |
| US7491406B2 (en) | 1998-09-25 | 2009-02-17 | Mcneil-Ppc, Inc. | Fast dissolving orally consumable films |
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| US7648712B2 (en) | 2000-03-23 | 2010-01-19 | Mcneil-Ppc, Inc. | Fast dissolving orally consumable films containing a taste masking agent |
| WO2017186399A1 (en) * | 2016-04-29 | 2017-11-02 | Henkel Ag & Co. Kgaa | Toothpaste for improving gum adhesion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006327277B2 (en) | Water-soluble films comprising low-viscosity alginates | |
| KR100890180B1 (en) | Oral preparations and supports for oral preparations | |
| FI88108B (en) | ORGANIC FREQUENCY PROCESSING, PHARMACEUTICAL, FAST COMPOSITION WITH PROLONGERED EFFECT | |
| RU2437648C2 (en) | Foamed lozenge containing grafted copolymer of polyvinyl alcohol and polyethylene glycol | |
| US20040208931A1 (en) | Fast dissolving films for oral administration of drugs | |
| JP2007502839A (en) | Composition for delivery of 5-HT agonist through oral mucosa and method of use thereof | |
| JP2009535397A (en) | Transmucosal composition | |
| KR20060135052A (en) | Preparation for oral administration | |
| JPH059412B2 (en) | ||
| KR100794264B1 (en) | Multilayer buccal mucoadhesive dosage forms | |
| CA2313618C (en) | Transmucosal formulations of levosimendan | |
| EP2889030A1 (en) | Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels | |
| JPS63250319A (en) | Pharmaceutical preparation suitable in oral cavity | |
| JPS63250318A (en) | Pharmaceutical preparation suitable in oral cavity | |
| CN107072204A (en) | System and method for mitigating opioid drug induction type euphoria | |
| JP2012031164A (en) | Film-shaped preparation | |
| JPH0967248A (en) | Preparation adhering to mucous membrane of oral cavity | |
| JP2003519641A (en) | Topical medicinal bioadhesive composition, and methods of use and preparation thereof | |
| JPS6222713A (en) | Mucosa adherent preparation | |
| AU758880B2 (en) | Timed release tablet comprising naproxen and pseudoephedrine | |
| JPS6115829A (en) | Sustained release nifedipine pharmaceutical for application to oral mucosa | |
| Upadhye et al. | A Review on Buccal Drug Delivery System | |
| Repka et al. | Matrix-and reservoir-based transmucosal delivery systems: tailoring delivery solutions | |
| Manikandan | Formulation Development and Invitro Evaluation of Cimetidine Buccal Patches | |
| MX2008007839A (en) | Water-soluble films comprising low-viscosity alginates |